Abstract
Chemokine CXC ligand 12 (CXCL12), originally named stromal cell-derived factor-1 (SDF-1), is a member of the CXC chemokine subfamily. CXCL12 is found to be expressed by all cell types that are presented in the central nervous system (CNS). It works in conjunction with the G-protein coupled receptor CXCR4, which is found at the surface of a variety of cells including neurons, astrocytes, microglia, bone marrow-derived cells, as well as other progenitor cells. Recent studies revealed that CXCL12 could also bind and signal through receptor CXCR7. CXCL12 and CXCR4 are constitutively expressed in the brain but are up-regulated in the ischemic penumbra regions following ischemic stroke. CXCL12/CXCR4 play important roles in multiple processes after ischemic stroke, which include inflammatory response, focal angiogenesis, and the recruitment of bone marrow-derived cells (BMCs) and neural progenitor cell (NPC) to injury. In addition to its roles in stroke pathology, CXCL12 is also thought to be a key regulator in stroke repairing. This review will focus on the function of CXCL12/CXCR4 in post-stroke inflammation and neurovascular repairing. The potential application of CXCL12 modulation in clinical stroke treatment is also discussed.
Keywords: Angiogenesis, CXCL12, CXCR4, CXCR7, inflammation, stroke, chemokine, ischemia, receptor, signaling pathways
Current Drug Targets
Title: Roles of Chemokine CXCL12 and its Receptors in Ischemic Stroke
Volume: 13 Issue: 2
Author(s): Yongting Wang, Jun Huang, Yaning Li and Guo-Yuan Yang
Affiliation:
Keywords: Angiogenesis, CXCL12, CXCR4, CXCR7, inflammation, stroke, chemokine, ischemia, receptor, signaling pathways
Abstract: Chemokine CXC ligand 12 (CXCL12), originally named stromal cell-derived factor-1 (SDF-1), is a member of the CXC chemokine subfamily. CXCL12 is found to be expressed by all cell types that are presented in the central nervous system (CNS). It works in conjunction with the G-protein coupled receptor CXCR4, which is found at the surface of a variety of cells including neurons, astrocytes, microglia, bone marrow-derived cells, as well as other progenitor cells. Recent studies revealed that CXCL12 could also bind and signal through receptor CXCR7. CXCL12 and CXCR4 are constitutively expressed in the brain but are up-regulated in the ischemic penumbra regions following ischemic stroke. CXCL12/CXCR4 play important roles in multiple processes after ischemic stroke, which include inflammatory response, focal angiogenesis, and the recruitment of bone marrow-derived cells (BMCs) and neural progenitor cell (NPC) to injury. In addition to its roles in stroke pathology, CXCL12 is also thought to be a key regulator in stroke repairing. This review will focus on the function of CXCL12/CXCR4 in post-stroke inflammation and neurovascular repairing. The potential application of CXCL12 modulation in clinical stroke treatment is also discussed.
Export Options
About this article
Cite this article as:
Wang Yongting, Huang Jun, Li Yaning and Yang Guo-Yuan, Roles of Chemokine CXCL12 and its Receptors in Ischemic Stroke, Current Drug Targets 2012; 13 (2) . https://dx.doi.org/10.2174/138945012799201603
DOI https://dx.doi.org/10.2174/138945012799201603 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Wnt / β-Catenin Signaling Pathway as Novel Cancer Drug Targets
Current Cancer Drug Targets Diffusion-Weighted Magnetic Resonance Imaging in Pelvic Cancer
Current Medical Imaging Lipid-based Self-Adjuvanting Vaccines
Current Drug Delivery Apoptosis Signaling Pathways in Anticancer Therapy
Current Cancer Therapy Reviews The Effects of Radix Curcumae Extract on Expressions of VEGF, COX-2 and PCNA in Gastric Mucosa of Rats Fed with MNNG
Current Pharmaceutical Biotechnology Inhibition of 17β -Hydroxysteroid Dehydrogenase (17β -HSD) by Imidazole-Based Compounds
Letters in Drug Design & Discovery Human Arylamine N-Acetyltransferase 1: A Drug-Metabolizing Enzyme and a Drug Target?
Current Drug Targets VEGF Inhibitors in Cancer Therapy
Current Pharmaceutical Design Targeting Autophagic Pathways by Plant Natural Compounds in Cancer Treatment
Current Drug Targets Biology of Cox-2: An Application in Cancer Therapeutics
Current Drug Targets Aromatase Inhibitors: A New Paradigm in Breast Cancer Treatment
Current Medicinal Chemistry - Anti-Cancer Agents Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development
Current Diabetes Reviews Combined Treatment with JFKD and Gefitinib Overcomes Drug Resistance in Non-Small Cell Lung Cancer
Current Pharmaceutical Biotechnology Melanoma Differentiation Associated Gene-7 (mda-7)/ Interleukin-24 (IL-24), mda-7/IL-24: Current Perspectives on a Unique Member of the IL-10 Family of Cytokines
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies
Current Pharmaceutical Design Congenital Malformations Attributed to Prenatal Exposure to Cyclophosphamide
Anti-Cancer Agents in Medicinal Chemistry Law-Medicine Interfacing: Patenting of Human Genes and Mutations
Recent Patents on DNA & Gene Sequences A Pilot Study for Investigation of Plasma Amino Acid Profile in Neurofibromatosis Type 1 Patients
Combinatorial Chemistry & High Throughput Screening Vitamin E and Prostate Cancer: Current Evidence and Future Directions
Current Nutrition & Food Science EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets